Immunotherapy plus chemo before ovarian cancer surgery
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage 3 or 4) ovarian, fallopian tube, or primary peritoneal cancer that started on the surface of the ovary or lining.
- You are between 18 and 75 years old.
- You are healthy enough to have surgery to remove your cancer, and at least one tumor can be measured on a scan.
- You have not had immunotherapy before.
- You agree to use effective birth control if you could become pregnant, and have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.